Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711671 | 0.88 | SCN9A (0.53) | SCN9AKMT2AMAPTMEN1SCN5A | |
| SCHEMBL713939 | 0.85 | SCN9A (0.70) | SCN9AMAPTSCN5ASMN1; SMN2 | |
| SCHEMBL714024 | 0.77 | SCN9A (0.57) | SCN9AKMT2AMEN1SCN5A | |
| SCHEMBL712134 | 0.76 | SCN9A (0.62) | SCN9AKMT2AMEN1SCN5AALDH1A1 | |
| SCHEMBL13962917 | 0.75 | SCN9A (0.45) | SCN9AKMT2AMAPTMEN1SMN1; SMN2 | |
| SCHEMBL710936 | 0.75 | SCN9A (0.56) | SCN9ASCN5A | |
| SCHEMBL711919 | 0.73 | SCN9A (0.67) | SCN9AMAPTSCN5ASMN1; SMN2 | |
| SCHEMBL712335 | 0.71 | SCN9A (0.60) | SCN9AMAPTSCN5ASMN1; SMN2 | |
| SCHEMBL712077 | 0.71 | SCN9A (0.59) | SCN9AMAPTSCN5A | |
| SCHEMBL207331 | 0.70 | MAPT (0.46) | KMT2AMAPTMEN1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2173743-A2 | SODIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2009012242-A2 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | SCN9A 17/4885KMT2A 1945/4885MAPT 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.